Double your impact Match My Donation
Dr. Matthew Hellmann of Memorial Sloan Kettering Cancer Center discusses new FDA approvals, clinical trials, and potential treatments for patients with small cell lung cancer.
Dr. Rony Dahan of Weizmann Institute of Science (Israel) discusses the latest advances in targeted antibodies for the effective treatment of many forms of cancer.
Caregivers Casey Zmudzinski and Benny Juarez discuss how they advocate for the best care possible for their loved ones.
Two cancer patients—Stephen Estrada and Mary Elizabeth Williams—discuss how they regained control after their cancer diagnosis
Dr. Gavin Dunn of Washington University in St. Louis discusses how cancer vaccines are capable of educating patients’ immune systems and have the potential to improve the immune system’s ability to target and eliminate cancer.
Dr. Kunle Odunsi of the Roswell Park Comprehensive Cancer Institute discusses how biomarkers are used to help patients today as well as how we’re working to harness the full potential of biomarkers moving forward.
Dr. Philip Greenberg of the University of Washington discusses how cutting-edge strategies using T cells from patients’ blood are currently being used in the clinic as well as how they might be improved moving forward.
Ariella Chivil, a patient advocate, and Dr. Alexander M. Lesokhin, her oncologist, discuss the nuances of communicating and informing both doctor and patient while on immunotherapy.
Dr. John Bell of the University of Ottawa and the Ontario Institute for Cancer Research discussses strategies that re-program viruses so that they selectively infect and kill cancer cells while leaving healthy cells and tissues unharmed.
Cancer patients T.J. Sharpe and Donna Fernandez share their experiences with immunotherapy and advice for patients currently seeking or receiving immunotherapy treatment.
Patrick Meins of EmergingMed will answer common questions around cancer clinical trials including trial definitions, eligibility criteria, and how to search for the right one.
Dr. James P. Allison of MD Anderson discusses how some proteins in immune cells act as "brakes" on the immune system response and how checkpoint inhibitors can be used to “release the brakes,” allowing a stronger immune attack against cancer.
Dr. Jedd D. Wolchok of Memorial Sloan Kettering Cancer Center discusses the latest developments in patient care including: checkpoint blockade, cancer vaccines, combination therapies, CAR T cell therapy, T cell receptor therapies, and neoantigens.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, can now receive PD-1 immunotherapy for treatment.
Sixteen Team CRI runners ran the 26.2 mile 2018 TCS New York City Marathon and raised an impressive total of $110,000.